Research is ongoing to find new, safe, effective treatments for COVID-19.

To date (as of 10/24/21):

  • the FDA has approved one antiviral medication, remdesivir, for use in patients whose symptoms are severe enough to require hospitalization

  • the FDA has granted Emergency Use Authorization for:

    • Treatment with monoclonal antibody infusions for:

      • patients who have a positive COVID-19 test within the past 10 days and have not yet been admitted to the hospital and

      • Are 12 years of age or older (and at least 40 kg) and

      • Are high risk for developing severe COVID-19 due to one of the following risk factors:

        • age 65 or older​

        • Overweight (body mass index over 25)

        • Pregnancy

        • Chronic kidney disease

        • Diabetes (Type 1 and Type 2)

        • Weakened immune system or are currently receiving immunosuppressive treatment

        • Cardiovascular disease/hypertension

        • Chronic lung disease

        • Sickle cell disease

        • Neurodevelopmental disorders

        • Medical-related technological dependence

    • Post-exposure prophylaxis (prevention) with monoclonal antibody infusions for COVID-19 in anyone who:

      • has had close exposure to COVID-19 and

      • is 12 years of age or older (and weighs at least 40 kg), and 

      • is at high risk for progression to severe COVID-19 due to one of the above risk factors and 

      • is not fully vaccinated, or is ​vaccinated but immunocompromised 

  • Other medications and treatment protocols for hospitalized patients depend on the severity of illness, underlying medical conditions, and comorbidities at the time of hospitalization. Available treatments are constantly evolving based on new data and guidelines.​


While there has been much press coverage of medications such as Plaquenil (hydroxychloroquine) and ivermectin, these are NOT recommended at this time for treatment or prophylaxis against COVID-19.

updated 10/24/21